Payment overview · 2025
General Payments
$6,035.74
76 reported records · 22 companies
Healthcare provider profile · identity verified
Vinod Namana
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · MUNSTER, IN · NPI 1902229784
Verified facts
What the public records show
CMS Open Payments records show Vinod Namana received $6,035.74 in general payments during 2025 across 76 reported records.
AngioDynamics, Inc. accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $2,944.90 | 48.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,504.55 | 24.9% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$464.99 | 7.7% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $325.05 | 5.4% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.11 | 2.3% | 6 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.33 | 1.2% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $70.55 | 1.2% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $50.69 | 0.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.65 | 0.8% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $49.42 | 0.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $38.46 | 0.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.00 | 0.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.12 | 0.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $22.93 | 0.4% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $19.87 | 0.3% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $18.84 | 0.3% | 1 | 2025 |
| Thrombolex, Inc. | Unresolved — no canonical attribution shown | $17.82 | 0.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $16.73 | 0.3% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $15.84 | 0.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.22 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.67 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $3,317.37 | 10 |
| Food and Beverage | $2,667.68 | 65 |
| Long term medical supply or device loan | $50.69 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $1,780.60 | 2 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $1,504.55 | 10 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $973.80 | 3 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $349.28 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $325.05 | 22 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $190.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $136.11 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $71.33 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $70.55 | 2 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $60.81 | 3 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $54.90 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - ELI 280 Normalized: hillrom eli 280 |
Device | Baxter Healthcare | $50.69 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $50.65 | 2 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $49.42 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $34.00 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.12 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Bashir Endovascular Catheter Normalized: bashir endovascular catheter |
Device | Thrombolex, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16.73 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 73 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
212 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 204 |
| Metoprolol Succinate | Metoprolol Succinate | 411 | 143 |
| Clopidogrel | Clopidogrel Bisulfate | 332 | 110 |
| Carvedilol | Carvedilol | 324 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 105 |
| Furosemide | Furosemide | 247 | 114 |
| Eliquis | Apixaban | 244 | 73 |
| Entresto | Sacubitril/Valsartan | 212 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 63 |
| Xarelto | Rivaroxaban | 179 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 172 | 63 |
| Losartan Potassium | Losartan Potassium | 166 | 50 |
| Lisinopril | Lisinopril | 165 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 54 |
| Amiodarone Hcl | Amiodarone Hcl | 138 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 41 |
| Spironolactone | Spironolactone | 112 | 43 |
| Flecainide Acetate | Flecainide Acetate | 108 | 27 |
| Alprazolam | Alprazolam | 85 | 16 |
| Brilinta | Ticagrelor | 82 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 26 |
| Metformin Hcl | Metformin Hcl | 74 | 22 |
| Warfarin Sodium | Warfarin Sodium | 63 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 24 |
| Digoxin | Digoxin | 58 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 17 |
| Simvastatin | Simvastatin | 50 | 14 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Potassium Chloride | Potassium Chloride | 44 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 16 |
| Montelukast Sodium | Montelukast Sodium | 43 | 19 |
| Nifedipine Er | Nifedipine | 40 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | 12 |
| Omeprazole | Omeprazole | 35 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 35 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 15 |
| Gabapentin | Gabapentin | 32 | 13 |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Metolazone | Metolazone | 25 | 12 |
| Valsartan | Valsartan | 25 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,035.74 · 76 records | AngioDynamics, Inc. | ABRE, ALPHAVAC, AMVUTTRA, ANGIOVAC, AURYON LASER SYSTEM 100-120 VAC, Assure WCD, Bashir Endovascular Catheter, CAMZYOS, CLEVIPREX, EVKEEZA, FFRct, HAWKONE, Hillrom - ELI 280, JARDIANCE, KENGREAL, LEQVIO, LifeVest, MYNX CONTROL VENOUS, OPSUMIT, PURIFIED CORTROPHIN GEL, REPATHA, TURBOHAWK, UPTRAVI, VERQUVO, Veozah, WATCHMAN FLX, Wegovy, XACT | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error